The impact of severe cardiovascular disease and critical limb ischemia (CLI) on the bone marrow (BM) is largely unknown.
C ritical limb ischemia (CLI), the most advanced stage of peripheral artery disease (PAD), is associated with high risk for major amputation and death. It is characterized by obstruction of the lower limb arteries and an impaired neovascularization response. Patients with cardiovascular disease, including CLI, have low levels of circulating progenitor cells (PCs), which may contribute to their impaired neovascularization response. 1, 2 The low PC levels have been suggested to be secondary to alterations at the bone marrow (BM) level; however, the effects of CLI on BM structure in humans have not been reported.
Animal studies have shown that diabetes mellitus, which is a major risk factor for cardiovascular disease and associated with impaired mobilization of PCs from the BM, 1,3-5 induces pathological processes in the BM, including niche dysfunction, 5 altered cytokine signaling, 3 and BM vasculopathy 6 and neuropathy, 7 which relate to impaired PC function and mobilization. In a recent issue of Circulation Research, Spinetti et al 8 for the first time provided evidence for a detrimental effect of type-2 diabetes mellitus on human BM, causing a reduction of hematopoietic tissue, fat deposition, and microvascular rarefaction, particularly when associated with CLI. Although their findings suggest that severity of systemic vascular disease affects BM remodeling, their study does not allow conclusions on the impact of CLI in the absence of diabetes mellitus, as they did not include patients with CLI without diabetes mellitus. In this Short Communication, we confirm and extend the observations of Spinetti et al by studying BM microvascular and neuropathic changes in patients with CLI with and without diabetes mellitus.
Methods
Detailed Methods are available in the Online Data Supplement.
Study Population and Protocol
Iliac crest biopsies were obtained from 33 patients with CLI, included in the Juventas trial (NCT00371371) 9 and 12 age-and sex-matched controls. The study complied with the Declaration of Helsinki and was approved by the local institutional review board. Informed consent was obtained.
Tissue samples were formalin-fixed, decalcified, and paraffin-embedded before immunohistochemical staining. Histomorphometry was performed on hematoxylin and eosin-stained sections. Microvascular, arteriolar, sympathetic nerve, and pan-neuronal structures were quantified using CD34-based, α-smooth muscle actin-based, tyrosine hydroxylase-based, and protein gene product 9.5-based protocols, respectively. Scoring researchers were blinded to biopsy origin.
Results

Subject Characteristics
Groups did not differ with respect to age or sex ( Table 1 ). Thirteen of the 33 patients with CLI had a history of diabetes mellitus and used glucose-lowering medication. Patients with CLI had a substantial burden of cardiovascular risk factors and comorbidities, which was not significantly different between patients with CLI with and without diabetes mellitus.
CLI Induces Alterations in BM Vasculature and Innervation
Less microvessels, that is, capillaries and sinusoids, were present in BM of patients with CLI compared with healthy controls (32.3±3.0 versus 40.2±1.7 microvessels/mm 2 ; P=0.01; Table 2 ; Figure 1 ). BM arteriolar density was not different between patients with CLI and controls (P=0.86). The number of arterioles reached by protein gene product 9.5-positive nerve endings was less in CLI BM (P=0.006), as was the number of sympathetic nerve terminals in CLI BM, compared with controls (P=0.047; Figure 2 ).
CLI Induces Alterations in BM Microvascular Density and Innervation Independent of Diabetes Mellitus Presence
Between patients with CLI with (n=13) and without diabetes mellitus (n=20), no differences in BM microvascular density (P=0.87) and BM nerve density (P=0.37 and P=0.57 for tyrosine hydroxylase and protein gene product 9.5, respectively) were observed. Arteriolar density was higher in patients with CLI with versus without diabetes mellitus (P=0.008) and not influenced by other characteristics including cardiovascular risk factors and baseline characteristics. We found no significant correlations between presence of diabetes mellitus and the other BM characteristics. In patients with CLI without diabetes mellitus, numbers of microvessels (32.8±1.8 versus 40.2±1.7/ mm 2 ; P=0.009), sympathetic nerve terminals (6.4±0.8 versus 10.1±1.8/mm 2 ; P=0.067), and number of arterioles reached by protein gene product 9.5-positive nerve endings (0.094±0.22 versus 0.20±0.03/mm 2 ; P=0.003) were lower than in controls.
Discussion
In this Short Communication, we show for the first time that CLI, also in the absence of diabetes mellitus, is associated with structural changes in the BM, characterized by lower microvascular density and reduced general as well as sympathetic innervation. Our findings confirm and extend the observations of Spinetti et al 8 ‡Hypertension was defined as having systolic blood pressure ≥140 mm Hg or diastolic blood pressure ≥90 mm Hg, or antihypertensive drug use. §Hyperlipidemia was defined as having blood levels of total cholesterol ≥6.50 mmol/L, triglycerides ≥2.3 mmol/L, or HDL-cholesterol ≤1.0 mmol/L, or lipidlowering drug use.
||Hyperhomocysteinemia was defined as having homocysteine blood levels of >19 μmol/L in men and >17 μmol/L in women.
¶Renal insufficiency was defined as having creatinine blood levels >120 μmol/L.
Spinetti et al 8 reported microvascular changes, alterations in BM composition and PC content in patients with diabetes mellitus and showed most striking microvascular remodeling in patients with CLI and diabetes mellitus. However, they performed their analyses in patients with CLI on the proximal part of the amputated femoral bone, which may have influenced their results. We obtained BM from the iliac crest in patients with CLI and controls, excluding effects from variances in BM structure in different anatomic areas and confirm the microvascular changes observed by Spinetti et al. Moreover, our study included patients with CLI with and without diabetes mellitus, showing similar changes in microvasculature, suggesting that CLI in itself, independent of diabetes mellitus, induces microvascular changes in the human BM.
In addition to the difference in microvasculature between patients with CLI and controls, we found that CLI is associated with a marked reduction in general and sympathetic innervation of the BM. It has been shown that neuronal impulses, especially of the sympathetic nervous system, regulate PC proliferation in and egress from the BM 10, 11 and that diabetic neuropathy in animals extends to the BM and results in impaired endothelial PC release. 7 However, no previous studies have addressed the relation between vascular disease in humans and altered innervation of the BM. Our data suggest that impaired general and sympathetic innervation of the BM may contribute to disturbed PC homeostasis and impaired mobilization of PCs from the BM in CLI.
Altogether, our observational study shows that CLI, irrespective of diabetes mellitus, is associated with microvascular rarefaction and impairment of sympathetic innervation in the human BM. Our data do not allow conclusions on causality or underlying mechanisms but suggest that CLI induces alterations in BM structure which may contribute to the reduced Numbers are mean±SEM. CLI indicates critical limb ischemia; CLI-DM, critical limb ischemia with diabetes mellitus; and PGP9.5, protein gene product 9.5. circulating PC counts in CLI and reflect impaired vasculoregenerative potential.
